Sage Therapeutics
CAMBRIDGE, MA · Founded 2010 · CIK 0001597553 · Biotech · Acquired
GABA-A and NMDA receptor modulating therapeutics for CNS disorders
sagerx.com →- Grants
- $225K
- 2 awards
- Sector median: 1
- Raised
- $698M
- 3 Form D · Jan 2021
- 69 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 12 granted · 28 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201320142015201620172018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · U01 · Neuroactive Steroid GABAA Receptor Positive Modulators for Fragile X Syndrome | $162,500 | |
| Federal grant | Department of Health and Human Services · U01 · Neuroactive Steroid GABAA Receptor Positive Modulators for Fragile X Syndrome | $62,748 | |
| Private capital raised | Form D · SEC | $10,000,000 | |
| Private capital raised | Form D · SEC | $38,000,000 | |
| Private capital raised | Form D · SEC | $649,986,998 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2888 | RESVERLOGIX CORP. | — | $12M |
| 2889 | Cullinan Therapeutics | — | — |
| 2890 | Network Music Partners, LLC | — | $205K |
| 2891 | Sage Therapeutics | — | $698M |
| 2892 | OTHRO THERAPEUTICS, INC. | — | — |
| 2893 | Santa Ana Bio, Inc. | — | $63M |
| 2894 | General Specific Inc. | — | $1.5M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Elizabeth BarrettDirector
- Michael CloonanExecutive Officer
- Michael ColaDirector
- Anne Marie CookExecutive Officer
- James FratesDirector
- Geno GermanoDirector
- George GolumbeskiDirector
- Barry GreeneDirector · Executive Officer
- Kimi IguchiExecutive Officer
- Jeffery JonasDirector · Executive Officer
- Jeffrey JonasDirector · Executive Officer
- Stephen KanesExecutive Officer
- Robert NelsenDirector
- Steven PaulDirector
- Albert RobichaudExecutive Officer
- Kevin StarrDirector
Patents
- Neuroactive Steroids Substituted In Position 10 With A Cyclic Group For Use In The Treatment Of Cns Disordersgranted
- Neuroactive Steroids And Their Methods Of Usegranted
- C17, C20, And C21 Substituted Neuroactive Steroids And Their Methods Of Usegranted
- Oxysterols And Methods Of Use Thereofapplication
- Neuroactive Steroids, Compositions, And Uses Thereofapplication
- Neuroactive Steroids, Compositions, And Uses Thereofapplication
- Compositions And Methods For Treating Cns Disordersapplication
- Compositions And Methods For Treating Cns Disordersapplication
- Compositions And Methods For Treating Cns Disordersgranted
- Neuroactive 19-ALKOXY-17-SUBSTITUTED Steroids, Prodrugs Thereof, And Methods Of Treatment Using Sameapplication
- Oxysterols And Methods Of Use Thereofgranted
- Crystalline Form Of A Neuroactive Steroidapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.